Skeletal Muscle-Directed FGF21 Gene Therapy Counteracts Obesity and Type 2 Diabetes

被引：0
|
作者：
Bosch, Fatima [1 ,2 ,3 ]
Jambrina, Claudia [1 ,2 ,3 ]
Sacristan, Victor [1 ,2 ,3 ]
Casana, Estefania [1 ,2 ,3 ]
Munoz, Sergio [1 ,2 ,3 ]
Rodo, Jordi [1 ,2 ,3 ]
Darriba, Sara [1 ,2 ,3 ]
Garcia, Miquel [1 ,2 ,3 ]
Leon, Xavier [1 ,2 ,3 ]
Grass, Ignasi [1 ,2 ,3 ]
Jimenez, Veronica [1 ,2 ,3 ]
机构：
[1] Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, Bellaterra, Spain
[2] Univ Autonoma Barcelona, Sch Vet Med, Bellaterra, Spain
[3] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
来源：
MOLECULAR THERAPY | 2019年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
796
引用
收藏
页码：369 / 369
页数：1
相关论文
共 50 条
  • [41] ASSOCIATIONS OF CHEMERIN AND FGF21 WITH SUBCLINICAL ATHEROSCLEROSIS AND ADVERSE LIPID METABOLISM IN TYPE 2 DIABETES
    Park, H. -K.
    Kim, H. -J.
    Byun, D. -W.
    Yoo, M. -H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S60 - S60
  • [42] FGF-21, Its Receptors and Target Genes in Skeletal Muscle and Adipose Tissue in Obesity and Type 2 Diabetes: Effects of Insulin and Exercise Training
    Kruse, Rikke
    Vienberg, Sara G.
    Vind, Birgitte F.
    Andersen, Birgitte
    Hojlund, Kurt
    DIABETES, 2016, 65 : A479 - A479
  • [43] Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes
    Ye, Xianlong
    Qi, Jianying
    Yu, Dan
    Wu, Yunzhou
    Zhu, Shenglong
    Li, Shujie
    Wu, Qiang
    Ren, Guiping
    Li, Deshan
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (04) : 726 - 734
  • [44] Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy
    Guse, Kilian
    Suzuki, Masataka
    Sule, Gautam
    Bertin, Terry K.
    Tyynismaa, Henna
    Ahola-Erkkila, Sofia
    Palmer, Donna
    Suomalainen, Anu
    Ng, Philip
    Cerullo, Vincenzo
    Hemminki, Akseli
    Lee, Brendan
    HUMAN GENE THERAPY, 2012, 23 (10) : 1065 - 1070
  • [45] Muscle-directed gene therapy for phenylketonuria with self-complementary AAV vectors
    Kume, A.
    Yagi, H.
    Mizukami, H.
    Urabe, M.
    Tsukahara, T.
    Uchibori, R.
    Ozawa, K.
    HUMAN GENE THERAPY, 2011, 22 (10) : A49 - A50
  • [46] FGF21 activation-mediated islet autophagy in Type 2 diabetes with pharmacotherapeutic potential
    Leung, Po Sing
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (07) : 641 - 644
  • [47] Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
    Charles, Edgar D.
    Neuschwander-Tetri, Brent A.
    Frias, Juan Pablo
    Kundu, Sudeep
    Luo, Yi
    Tirucherai, Giridhar S.
    Christian, Rose
    OBESITY, 2019, 27 (01) : 41 - 49
  • [48] Dysregulation of early gene response to a mixed meal in skeletal muscle in obesity and type 2 diabetes
    Makhnovskii, Pavel A.
    Lednev, Egor M.
    Gavrilova, Alina O.
    Kurochkina, Nadia S.
    Vepkhvadze, Tatiana F.
    Shestakova, Marina V.
    Popov, Daniil V.
    PHYSIOLOGICAL GENOMICS, 2023, 55 (10) : 468 - 477
  • [49] Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice
    Queen, Nicholas J.
    Bates, Rhiannon
    Huang, Wei
    Xiao, Run
    Appana, Bhavya
    Cao, Lei
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 20 : 409 - 422
  • [50] FGF21 is Produced By Active Skeletal Muscle during Intense Exercise in Humans: Influence Of PIO2
    Martin-Rincon, Marcos
    Perez-Lopez, Alberto
    Azzinnari, Marco
    Said-Quintana, Mercedes
    Santana, Alfredo
    Morales-Alamo, David
    Dorado-Garcia, Cecilia
    Calbet, Jose A. L.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2017, 49 (05) : 88 - 89
12345